Antibody Drug Conjugates Global Market Report 2024

Description

Antibody-drug conjugates (ADCs) are medications specifically designed to deliver chemotherapy to cancer cells. They consist of a cytotoxic drug linked to a monoclonal antibody, which binds to a specific target expressed on cancer cells. Upon binding to the target, the ADC releases a cytotoxic chemical into the cancer cell, aiming to destroy it.

The main components of antibody-drug conjugates include monoclonal antibodies, linkers, drugs or toxins, and others. Monoclonal antibodies are generated by cloning a single white blood cell, and each subsequent antibody is derived from a single parent cell. Some examples of ADC products include Adcetris, Kadcyla, and others. Various technologies, such as immunogen technology, Seattle Genetics technology, immunomedics technology, among others, are involved in the development of antibody-drug conjugates. These therapies find applications in treating conditions such as blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumors, and others, and are implemented in hospitals, clinics, and other healthcare settings.

The antibody-drug conjugates (ADCs) market research report is one of a series of new reports from The Business Research Company that provides antibody-drug conjugates (ADCs) market statistics, including antibody-drug conjugates (ADCs) industry global market size, regional shares, competitors with an antibody-drug conjugates (ADCs) market share, detailed antibody-drug conjugates (ADCs) market segments, market trends and opportunities, and any further data you may need to thrive in the antibody-drug conjugates (ADCs) industry. This antibody-drug conjugates (ADCs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antibody drug conjugates market size has grown exponentially in recent years. It will grow from $8.78 billion in 2023 to $10.7 billion in 2024 at a compound annual growth rate (CAGR) of 21.9%. The growth observed during the historical period in the antibody-drug conjugates (ADCs) market can be attributed to factors such as the increasing prevalence of cancer, successful clinical outcomes leading to regulatory approvals, strategic collaborations between pharmaceutical companies, a rise in investment in research and development (R&D) initiatives, and the implementation of market expansion strategies.

The antibody drug conjugates market size is expected to see exponential growth in the next few years. It will grow to $24.8 billion in 2028 at a compound annual growth rate (CAGR) of 23.4%. The anticipated growth in the forecast period in the antibody-drug conjugates (ADCs) market can be attributed to factors such as the development of next-generation ADCs, expanding indications for their use, an increasing focus on personalized medicine in cancer treatment, rising investment in precision medicine approaches, and a growing awareness of healthcare options. Major trends expected in the forecast period include advancements in conjugation technologies, an improved understanding of tumor biology influencing ADC development, ongoing technological advancements in the field, expanding therapeutic applications for ADCs, and the continuous evolution of advanced conjugation technologies for enhanced drug delivery.

The global antibody-drug conjugates market is witnessing significant growth driven by the increasing incidence of cancer worldwide. Primary causes of most cancers, including obesity, smoking, alcohol consumption, and poor dietary habits, contribute to a rising trend. Cancer Research UK projects a substantial increase, estimating 27.5 million new cancer cases annually by 2040. This surge in cancer incidences is expected to boost the demand for antibody-drug conjugates, thereby propelling market growth.

The upward trajectory of the antibody-drug conjugates market is further fueled by a growing number of clinical trial studies. Clinical trials, essential for testing new treatments and interventions, play a crucial role in disease management. Antibody-drug conjugates, as a significant category of anti-cancer medications, are undergoing numerous clinical trials for treating blood-related cancers and solid tumors. Notably, there has been a substantial increase in registered clinical trials worldwide, with 452,604 listed on ClinicalTrials.gov, as reported by The Xtalks in May 2023. This uptrend indicates the rising prominence of clinical studies, contributing to the expansion of the antibody-drug conjugates market.

Challenges in the manufacturing process of antibody-drug conjugates act as a restraint on market growth. ADC manufacturing facilities require substantial capital investment and specialized training for operators. The complexity of ADC process development, involving additional steps not present in conventional monoclonal antibody manufacturing, poses operational difficulties. Challenges include optimizing antibody-drug conjugation reactions and subsequent drug substance purification, along with the need for aseptic environments and protection of personnel from highly toxic drug compounds.

Manufacturers of antibody-drug conjugates are subject to monitoring by regulatory bodies, such as the Food and Drug Administration (FDA) in the USA. Although there is no specific regulatory guidance for ADC development, the FDA follows existing guidelines for small drugs and monoclonal antibodies to regulate ADC. Regulatory oversight focuses on aspects such as the manufacturing of the antibody component, control strategy for antibody intermediate, drug substance, and drug product. Small molecule review groups at the FDA play a key role in evaluating payload and linker adequacy, conjugation reactions, and aspects of the control strategy.

Manufacturers are increasingly engaging in collaborations and partnerships to share technology, resources, and product knowledge. An example is the collaboration between Sanofi, a French multinational pharmaceutical company, and Seagen Inc., a US biotechnology company, announced in March 2022. This collaboration aims to develop and market up to three cancer targets for antibody-drug conjugates, leveraging Sanofi's exclusive monoclonal antibody technology and Seagen's exclusive ADC technology. Such collaborations enhance synergies, fostering the creation of candidate medications to offer new hope to cancer patients.

Major companies in the antibody-drug conjugates market are introducing innovative breakthrough conjugates such as Ujvira to offer affordable new therapies. Ujvira, launched by Zydus Cadila in May 2021, is the world's first biosimilar antibody-drug conjugate of trastuzumab emtansine. This breakthrough treatment targets breast and stomach cancer by inhibiting the human epidermal growth factor receptor protein (HER2). Administered by qualified medical professionals, Ujvira represents a significant advancement in cancer therapy.

Major companies operating in the antibody drug conjugates market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Sorrento Therapeutics Inc., Astellas Pharma Inc., Biogen Inc., Zydus Lifesciences Limited, Seagen Inc., Seagen Inc., Progenics Pharmaceuticals Inc., Synthon BV, Genentech Inc., ImmunoGen Inc., Nordic Nanovector ASA, ADC Therapeutics SA, Immunomedics Inc., Mersana Therapeutics Inc., Heidelberg Pharma AG, Celldex Therapeutics Inc., Oxford BioTherapeutics, Concortis Biotherapeutics Corp., Antikor BioPharma Ltd., Fredax, Eisai Co. Ltd., Merck KGaA, Bracco S.p.A.

North America was the largest region in the antibody-drug conjugates (ADCs) market in 2023. The Middle East is expected to be the fastest-growing region in the global antibody drug conjugates market share during the forecast period. The regions covered in the antibody drug conjugates market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antibody drug conjugates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The antibody-drug conjugates (ADCs) market consists of sales of enfortumab vedotin, sacituzumab govitecan, trastuzumab emtansine, and trastuzumab deruxtecan. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antibody Drug Conjugates Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antibody drug conjugates market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antibody drug conjugates ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antibody drug conjugates market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Type: Monoclonal Antibodies; Linker; Drug/Toxin; Other Types
2) By Product: Adcertis; Kadcyla; Other Products
3) By Technology: Immunogen Technology; Seattle Genetics Technology; Immunomedics Technology; Other Technology
4) By Application: Blood Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Brain Tumor; Other Applications
5) By End User: Hospital; Clinics; Other End Users
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Bayer AG; AstraZeneca plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r14984

1. Executive Summary

2. Antibody Drug Conjugates Market Characteristics

3. Antibody Drug Conjugates Market Trends And Strategies

4. Antibody Drug Conjugates Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Antibody Drug Conjugates Market Size and Growth

5.1. Global Antibody Drug Conjugates Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Antibody Drug Conjugates Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Antibody Drug Conjugates Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Antibody Drug Conjugates Market Segmentation

6.1. Global Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Monoclonal Antibodies
Linker
Drug/Toxin
Other Types
6.2. Global Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Adcertis
Kadcyla
Other Products
6.3. Global Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Immunogen Technology
Seattle Genetics Technology
Immunomedics Technology
Other Technology
6.4. Global Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Blood Cancer
Breast Cancer
Ovarian Cancer
Lung Cancer
Brain Tumor
Other Applications
6.5. Global Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital
Clinics
Other End Users

7. Antibody Drug Conjugates Market Regional And Country Analysis

7.1. Global Antibody Drug Conjugates Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Antibody Drug Conjugates Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Antibody Drug Conjugates Market

8.1. Asia-Pacific Antibody Drug Conjugates Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Antibody Drug Conjugates Market

9.1. China Antibody Drug Conjugates Market Overview
9.2. China Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Antibody Drug Conjugates Market

10.1. India Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Antibody Drug Conjugates Market

11.1. Japan Antibody Drug Conjugates Market Overview
11.2. Japan Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Antibody Drug Conjugates Market

12.1. Australia Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Antibody Drug Conjugates Market

13.1. Indonesia Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Antibody Drug Conjugates Market

14.1. South Korea Antibody Drug Conjugates Market Overview
14.2. South Korea Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Antibody Drug Conjugates Market

15.1. Western Europe Antibody Drug Conjugates Market Overview
15.2. Western Europe Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Antibody Drug Conjugates Market

16.1. UK Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Antibody Drug Conjugates Market

17.1. Germany Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Antibody Drug Conjugates Market

18.1. France Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Antibody Drug Conjugates Market

19.1. Italy Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Antibody Drug Conjugates Market

20.1. Spain Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Antibody Drug Conjugates Market

21.1. Eastern Europe Antibody Drug Conjugates Market Overview
21.2. Eastern Europe Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Antibody Drug Conjugates Market

22.1. Russia Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Antibody Drug Conjugates Market

23.1. North America Antibody Drug Conjugates Market Overview
23.2. North America Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Antibody Drug Conjugates Market

24.1. USA Antibody Drug Conjugates Market Overview
24.2. USA Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Antibody Drug Conjugates Market

25.1. Canada Antibody Drug Conjugates Market Overview
25.2. Canada Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Antibody Drug Conjugates Market

26.1. South America Antibody Drug Conjugates Market Overview
26.2. South America Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Antibody Drug Conjugates Market

27.1. Brazil Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Antibody Drug Conjugates Market

28.1. Middle East Antibody Drug Conjugates Market Overview
28.2. Middle East Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Antibody Drug Conjugates Market

29.1. Africa Antibody Drug Conjugates Market Overview
29.2. Africa Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Antibody Drug Conjugates Market Competitive Landscape And Company Profiles

30.1. Antibody Drug Conjugates Market Competitive Landscape
30.2. Antibody Drug Conjugates Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. F. Hoffmann-La Roche Ltd.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. AbbVie Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Bayer AG
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. AstraZeneca plc
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Antibody Drug Conjugates Market Other Major And Innovative Companies

31.1. GlaxoSmithKline plc
31.2. Takeda Pharmaceutical Company Limited
31.3. Millennium Pharmaceuticals Inc.
31.4. Gilead Sciences Inc.
31.5. Regeneron Pharmaceuticals Inc.
31.6. Daiichi Sankyo Company Limited
31.7. Sorrento Therapeutics Inc.
31.8. Astellas Pharma Inc.
31.9. Biogen Inc.
31.10. Zydus Lifesciences Limited
31.11. Seagen Inc.
31.12. Seagen Inc.
31.13. Progenics Pharmaceuticals Inc.
31.14. Synthon BV
31.15. Genentech Inc.

32. Global Antibody Drug Conjugates Market Competitive Benchmarking

33. Global Antibody Drug Conjugates Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Antibody Drug Conjugates Market

35. Antibody Drug Conjugates Market Future Outlook and Potential Analysis

35.1 Antibody Drug Conjugates Market In 2028 - Countries Offering Most New Opportunities
35.2 Antibody Drug Conjugates Market In 2028 - Segments Offering Most New Opportunities
35.3 Antibody Drug Conjugates Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer